Treprostinil (Tyvaso)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension, Pulmonary Hypertension Associated with Interstitial Lung Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Idiopathic Pulmonary Fibrosis · Phase 3 · under FDA review

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (11)
Idiopathic Pulmonary Fibrosis
Pulmonary Arterial Hypertension
NCT01908699 · Lung Biotechnology PBC
2013-05-31 – 2019-02-19 · Pulmonary Arterial Hypertension
What this study did
NCT01557660 · United Therapeutics
2012-06 – 2018-12 · Pulmonary Arterial Hypertension
What this study did
NCT02471183 · Actelion
2015-10-12 – 2016-12-05 · Pulmonary Arterial Hypertension
What this study did
NCT01557647 · United Therapeutics
2012-06 – 2016-06 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT05943535 · United Therapeutics
2023-10-30 – 2027-11 · Progressive Pulmonary Fibrosis, Interstitial Lung Disease
What this study did
NCT03794583 · United Therapeutics
2018-12-21 – 2022-11-29 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
What this study did
NCT03496623 · United Therapeutics
2018-05-08 – 2022-10-13 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT07923526 · United Therapeutics
2027-03 – 2034-09 · Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
What this study did
NCT02633293 · United Therapeutics
2016-09-15 – 2021-08-01 · Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
What this study did
Phase 2 (12)
Idiopathic Pulmonary Fibrosis
NCT00703339 · Lung Biotechnology PBC
2008-06 – 2009-12 · Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
What this study did
Pulmonary Arterial Hypertension
NCT07177703 · Shanghai Zhongshan Hospital
2025-10-31 – 2027-12-31 · Pulmonary Arterial Hypertension (PAH)
What this study did
NCT05564637 · Mayo Clinic
2023-03-13 – 2024-10-30 · Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
What this study did
NCT00705133 · Rajan Saggar
2008-07 – 2011-04 · Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT07923591 · United Therapeutics
2026-11 – 2028-05 · Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
What this study did
NCT07037836 · Bastiaan Driehuys
2025-09-29 – 2027-07-01 · COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
What this study did
NCT06969573 · University of Alberta
2025-06-05 – 2026-12-31 · COPD (Chronic Obstructive Pulmonary Disease)
What this study did
NCT03814317 · University of Florida
2020-01-30 – 2025-12-31 · Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
What this study did
NCT03012646 · United Therapeutics
2017-04 – 2019-04 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
What this study did
NCT02178566 · Inova Health Care Services
2015-08 – 2019-01 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02769624 · Children's Hospital Medical Center, Cincinnati
2017-02-21 – 2018-09-21 · Congenital Heart Disease
What this study did
NCT02370095 · University of North Carolina, Chapel Hill
2015-02 – 2017-11-07 · Respiratory Distress Syndrome, Adult
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT03654989 · University Hospital, Grenoble
2020-01-28 – 2021-12-07 · Diabetic Foot Ulcer
What this study did
NCT03120533 · University Hospital, Grenoble
2017-06-20 – 2019-06-03 · Scleroderma, Systemic
What this study did
NCT01554540 · University Hospital, Grenoble
2012-02 – 2014-02 · Scleroderma, Systemic
What this study did
NCT01082484 · University Hospital, Grenoble
2010-01 – 2011-01 · Healthy
What this study did
Phase 1 (8)
Pulmonary Arterial Hypertension
NCT04675944 · Bial - Portela C S.A.
2018-02-28 – 2018-05-25 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT07837830 · Valley Health System
2026-09 – 2028-06 · Pulmonary Hypertension
What this study did
NCT07116681 · University of California, San Diego
2025-10-01 – 2027-07-01 · Pulmonary Hypertension
What this study did
NCT01481974 · Abhinav Humar, MD
2012-12 – 2019-11-24 · Ischemia Reperfusion Injury
What this study did
NCT01758744 · University of Colorado, Denver
2012-12 – 2016-07 · Pulmonary Hypertension, COPD
What this study did
NCT02770521 · Eli Lilly and Company
2016-05 – 2016-07 · Healthy
What this study did
NCT06193031 · Insmed Incorporated
2015-11-17 – 2015-12-18 · Healthy Volunteers
What this study did
NCT03803163 · Ascendis Pharma A/S
2015-01 – 2015-06 · Healthy Volunteers
What this study did
Phase 4 (4)
Pulmonary Arterial Hypertension
NCT03835676 · Magdi H. Yacoub
2019-05-01 – 2025-12-01 · Pulmonary Hypertension
What this study did
NCT01268553 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2010-08 – 2016-10-05 · Pulmonary Arterial Hypertension
What this study did
NCT00741819 · United Therapeutics
2008-09 – 2010-12 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT01305252 · Stanford University
2010-07 – 2014-09 · Hypertension, Pulmonary
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02498444 · Stanford University
2015-09 – 2020-12 · Single Ventricle
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Other / comorbidity
NCT07844213 · China National Center for Cardiovascular Diseases
2022-08-25 – 2025-08-31 · Congenital Heart Disease, Pulmonary Hypertension
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Idiopathic Pulmonary Fibrosis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Treprostinil (Tyvaso): this drugPhase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Nerandomilast (Jascayd)ApprovedSmall moleculePDE4BReliable signal
NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5)
NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88)
Nintedanib (Ofev)ApprovedSmall moleculeTriple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Partial signal
NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results).
NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results).
Pirfenidone (Esbriet)ApprovedSmall moleculePyridoneReliable signal
NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results).
Treprostinil (Tyvaso DPI)
Approved(overall)
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 3Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
ABBV-722
Phase 1(overall)
Small moleculeLPAR1not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)not yet gradedNo reviewed efficacy summary in this indication
ZiritaxestatDiscontinuedSmall moleculeautotaxin (ENPP2)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Treprostinil (Tyvaso) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2COPD (Chronic Obstructive Pulmonary Disease)Active not recruiting
Est. primary completion 2026-12-31 · NCT06969573 · CT.gov ↗
What to watch
2027 (5)
July 2027 (2)
Phase 1Pulmonary HypertensionNot yet recruiting
Est. primary completion 2027-07-01 · NCT07116681 · CT.gov ↗
What to watch
Phase 2COPD (Chronic Obstructive Pulmonary Disease), HypoxemiaRecruiting
Est. primary completion 2027-07-01 · NCT07037836 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Progressive Pulmonary Fibrosis, Interstitial Lung DiseaseRecruiting
Est. primary completion 2027-11 · NCT05943535 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1Pulmonary HypertensionRecruiting
Est. primary completion 2027-12 · NCT07837830 · CT.gov ↗
What to watch
Phase 2Pulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2027-12-31 · NCT07177703 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Phase 2Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary DiseaseNot yet recruiting
Est. primary completion 2028-05 · NCT07923591 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 3Idiopathic Pulmonary FibrosisEnrolling by invitation
Est. primary completion 2029-12 · NCT04905693 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Phase 2/3Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary DiseaseNot yet recruiting
Est. primary completion 2034-09 · NCT07923526 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 September 2026Filing acceptedFDA accepts sNDA for nebulized Tyvaso in idiopathic pulmonary fibrosis
US, FDA · United Therapeutics Corporation · Source ↗
30 March 2026Topline resultTETON-1 (NCT04708782) Phase 3 of nebulized Tyvaso in IPF met its primary endpoint
United Therapeutics Corporation · Source ↗
2 September 2025Topline resultTETON-2 (NCT05255991) Phase 3 of nebulized Tyvaso in IPF met its primary endpoint
United Therapeutics Corporation · Source ↗